Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
Cellular Oncology
Published in: Cellular Oncology 4/2020

01-08-2020 | Metastasis | Original paper

The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis

Authors: Yangjiong Xiao, Yang Yu, Pengcheng Jiang, Yuhong Li, Chao Wang, Rong Zhang

Published in: Cellular Oncology | Issue 4/2020

Login to get access

Abstract

Purpose

The PI3K/AKT/mTOR pathway is one of the most highly activated cellular signaling pathways in advanced ovarian cancer. Although several PI3K/AKT/mTOR inhibitors have been developed to treat various types of cancer, the antitumor efficacy of many of these compounds against ovarian cancer has remained unclear.

Methods

Here, we tested and compared a panel of 16 PI3K/AKT/mTOR inhibitors (XL765, Miltefosine, Rapamycin, CCI-779, RAD001, FK506, XL147, GSK2110183, IPI-145, GSK2141795, BYL719, GSK458, CAL-101, XL765 analogue SAR245409, Triciribine, and GDC0941) that have entered clinical trials for antitumor activity against ovarian cancer, as well as the front line drug, paclitaxel. Antitumor efficacy was measured in both ovarian cancer cell lines and patient-derived ovarian primary tumor cell lines in vitro and in vivo.

Results

We identified the PI3K/mTOR dual inhibitor GSK458 as a potent inhibitor of proliferation in all cell lines tested at half maximal inhibitory concentrations (IC50) of approximately 0.01-1 µM, a range tens to hundreds fold lower than that of the other PI3K/AKT/mTOR inhibitors tested. Additionally, GSK458 showed the highest inhibitory efficacy against ovarian cancer cell migration. GSK458 also inhibited tumor growth and metastasis in nude mice intraperitoneally engrafted with SKOV3 cells or a patient-derived tumor cell xenograft (PDCX). Importantly, the inhibitory efficiency of GSK458 on cell proliferation and migration both in vitro and in vivo was comparable to that of paclitaxel. Mechanistically, the anti-tumor activity of GSK458 was found to be associated with inactivation of AKT and mTOR, and induction of cell cycle arrest at the G0/G1 phase.

Conclusions

Based on our results, we conclude that GSK458 may serve as an attractive candidate to treat ovarian cancer.
Appendix
Available only for authorised users
Literature
1.
F. Bray, J. Ferlay, I. Soerjomataram, R.L. Siegel, L.A. Torre, A. Jemal, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018)CrossRef
2.
R.L. Siegel, K.D. Miller, A. Jemal, Cancer statistics, 2018. CA Cancer J. Clin. 68, 7–30 (2018)CrossRef
3.
L.A. Torre, F. Bray, R.L. Siegel, J. Ferlay, J. Lortet-Tieulent, A. Jemal, Global cancer statistics, 2012. CA Cancer J. Clin. 65, 87–108 (2015)CrossRef
4.
X. Li, M. Tang, Q. Zhu, X. Wang, Y. Lin, X. Wang, The exosomal integrin alpha5beta1/AEP complex derived from epithelial ovarian cancer cells promotes peritoneal metastasis through regulating mesothelial cell proliferation and migration. Cell. Oncol. 43, 263–277 (2020)CrossRef
5.
S. Vaughan, J.I. Coward, R.C. Bast Jr., A. Berchuck, J.S. Berek, J.D. Brenton, G. Coukos, C.C. Crum, R. Drapkin, D. Etemadmoghadam, M. Friedlander, H. Gabra, S.B. Kaye, C.J. Lord, E. Lengyel, D.A. Levine, I.A. McNeish, U. Menon, G.B. Mills, K.P. Nephew, A.M. Oza, A.K. Sood, E.A. Stronach, H. Walczak, D.D. Bowtell, F.R. Balkwill, Rethinking ovarian cancer: recommendations for improving outcomes. Nat. Rev. Cancer 11, 719–725 (2011)CrossRef
6.
B.M. Reid, J.B. Permuth, T.A. Sellers, Epidemiology of ovarian cancer: a review. Cancer Biol. Med. 14, 9–32 (2017)CrossRef
7.
E. Pujade-Lauraine, J.A. Ledermann, F. Selle, V. Gebski, R.T. Penson, A.M. Oza, J. Korach, T. Huzarski, A. Poveda, S. Pignata, M. Friedlander, N. Colombo, P. Harter, K. Fujiwara, I. Ray-Coquard, S. Banerjee, J. Liu, E.S. Lowe, R. Bloomfield, P. Pautier, S.O.E.-O. investigators, Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 18, 1274–1284 (2017)
8.
J. Ledermann, P. Harter, C. Gourley, M. Friedlander, I. Vergote, G. Rustin, C.L. Scott, W. Meier, R. Shapira-Frommer, T. Safra, D. Matei, A. Fielding, S. Spencer, B. Dougherty, M. Orr, D. Hodgson, J.C. Barrett, U. Matulonis, Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancet Oncol. 15, 852–861 (2014)CrossRef
9.
A. Ghahremanloo, A. Soltani, S.M.S. Modaresi, S.I. Hashemy, Recent advances in the clinical development of immune checkpoint blockade therapy. Cell. Oncol. 42, 609–626 (2019)CrossRef
10.
J.R. Brahmer, S.S. Tykodi, L.Q. Chow, W.J. Hwu, S.L. Topalian, P. Hwu, C.G. Drake, L.H. Camacho, J. Kauh, K. Odunsi, H.C. Pitot, O. Hamid, S. Bhatia, R. Martins, K. Eaton, S. Chen, T.M. Salay, S. Alaparthy, J.F. Grosso, A.J. Korman, S.M. Parker, S. Agrawal, S.M. Goldberg, D.M. Pardoll, A. Gupta, J.M. Wigginton, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455–2465 (2012)CrossRef
11.
S.L. Gaillard, A.A. Secord, B. Monk, The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol. Oncol. Res. Pract. 3, 11 (2016)CrossRef
12.
J. Rodon, R. Dienstmann, V. Serra, J. Tabernero, Development of PI3K inhibitors: lessons learned from early clinical trials. Nat. Rev. Clin. Oncol. 10, 143–153 (2013)CrossRef
13.
S. Mabuchi, H. Kuroda, R. Takahashi, T. Sasano, The PI3K/AKT/mTOR pathway as a therapeutic target in ovarian cancer. Gynecol. Oncol. 137, 173–179 (2015)CrossRef
14.
N. Cancer Genome Atlas Research, Integrated genomic analyses of ovarian carcinoma. Nature 474, 609–615 (2011)
15.
M.L. Gasparri, E. Bardhi, I. Ruscito, A. Papadia, A.A. Farooqi, C. Marchetti, G. Bogani, I. Ceccacci, M.D. Mueller, P. Benedetti, Panici, PI3K/AKT/mTOR pathway in ovarian cancer treatment: Are we on the right track? Geburtshilfe Frauenheilkd. 77, 1095–1103 (2017)
16.
H. Li, J. Zeng, K. Shen, PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch. Gynecol. Obstet. 290, 1067–1078 (2014)CrossRef
17.
D.A. Altomare, H.Q. Wang, K.L. Skele, A. De Rienzo, A.J. Klein-Szanto, A.K. Godwin, J.R. Testa, AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth. Oncogene 23, 5853–5857 (2004)CrossRef
18.
P.L. Bedard, J. Tabernero, F. Janku, Z.A. Wainberg, L. Paz-Ares, J. Vansteenkiste, E. Van Cutsem, J. Perez-Garcia, A. Stathis, C.D. Britten, N. Le, K. Carter, D. Demanse, D. Csonka, M. Peters, A. Zubel, H. Nauwelaerts, C. Sessa, A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin. Cancer Res. 21, 730–738 (2015)CrossRef
19.
T.G. Granda, D. Cebrian, S. Martinez, P.V. Anguita, E.C. Lopez, W. Link, T. Merino, J. Pastor, B.G. Serelde, S. Peregrina, I. Palacios, M.I. Albarran, A. Cebria, M. Lorenzo, P. Alonso, J. Fominaya, A.R. Lopez, J.R. Bischoff, Biological characterization of ETP-46321 a selective and efficacious inhibitor of phosphoinositide-3-kinases. Invest. New Drugs 31, 66–76 (2013)CrossRef
20.
H. Tanaka, M. Yoshida, H. Tanimura, T. Fujii, K. Sakata, Y. Tachibana, J. Ohwada, H. Ebiike, S. Kuramoto, K. Morita, Y. Yoshimura, T. Yamazaki, N. Ishii, O. Kondoh, Y. Aoki, The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin. Cancer Res. 17, 3272–3281 (2011)CrossRef
21.
O. Treeck, B. Wackwitz, U. Haus, O. Ortmann, Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells. Gynecol. Oncol. 102, 292–299 (2006)CrossRef
22.
C.E. Kyriakopoulos, A.M. Braden, J.M. Kolesar, J.C. Eickhoff, H.H. Bailey, J. Heideman, G. Liu, K.B. Wisinski, A phase I study of tivantinib in combination with temsirolimus in patients with advanced solid tumors. Invest. New Drugs 35, 290–297 (2017)CrossRef
23.
K. Behbakht, M.W. Sill, K.M. Darcy, S.C. Rubin, R.S. Mannel, S. Waggoner, R.J. Schilder, K.Q. Cai, A.K. Godwin, R.K. Alpaugh, Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study. Gynecol. Oncol. 123, 19–26 (2011)CrossRef
24.
F. Janku, J.J. Wheler, S.N. Westin, S.L. Moulder, A. Naing, A.M. Tsimberidou, S. Fu, G.S. Falchook, D.S. Hong, I. Garrido-Laguna, R. Luthra, J.J. Lee, K.H. Lu, R. Kurzrock, PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J. Clin. Oncol. 30, 777–782 (2012)CrossRef
25.
A.C. Wong Te Fong, P. Thavasu, S. Gagrica, K.E. Swales, M.O. Leach, S.C. Cosulich, Y.L. Chung, U. Banerji, Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models. Oncotarget 8, 113874–113884 (2017)CrossRef
26.
F. Musa, A. Alard, G. David-West, J.P. Curtin, S.V. Blank, R.J. Schneider, Dual mTORC1/2 inhibition as a novel strategy for the resensitization and treatment of platinum-resistant ovarian cancer. Mol. Cancer Ther. 15, 1557–1567 (2016)
27.
I. Brana, N.A. Pham, L. Kim, S. Sakashita, M. Li, C. Ng, Y. Wang, P. Loparco, R. Sierra, L. Wang, B.A. Clarke, B.G. Neel, L.L. Siu, M.S. Tsao, Novel combinations of PI3K-mTOR inhibitors with dacomitinib or chemotherapy in PTEN-deficient patient-derived tumor xenografts. Oncotarget 8, 84659–84670 (2017)CrossRef
28.
A. Kudoh, T. Oishi, H. Itamochi, S. Sato, J. Naniwa, S. Sato, M. Shimada, J. Kigawa, T. Harada, Dual inhibition of phosphatidylinositol 3’-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach for mucinous adenocarcinoma of the ovary. Int. J. Gynecol. Cancer 24, 444–453 (2014)CrossRef
29.
T. Kashiyama, K. Oda, Y. Ikeda, Y. Shiose, Y. Hirota, K. Inaba, C. Makii, R. Kurikawa, A. Miyasaka, T. Koso, T. Fukuda, M. Tanikawa, K. Shoji, K. Sone, T. Arimoto, O. Wada-Hiraike, K. Kawana, S. Nakagawa, K. Matsuda, F. McCormick, H. Aburatani, T. Yano, Y. Osuga, T. Fujii, Antitumor activity and induction of TP53-dependent apoptosis toward ovarian clear cell adenocarcinoma by the dual PI3K/mTOR inhibitor DS-7423. PLoS One 9, e87220 (2014)CrossRef
30.
J.F. Liu, S. Palakurthi, Q. Zeng, S. Zhou, E. Ivanova, W. Huang, I.K. Zervantonakis, L.M. Selfors, Y. Shen, C.C. Pritchard, M. Zheng, V. Adleff, E. Papp, H. Piao, M. Novak, S. Fotheringham, G.M. Wulf, J. English, P.T. Kirschmeier, V.E. Velculescu, C. Paweletz, G.B. Mills, D.M. Livingston, J.S. Brugge, U.A. Matulonis, R. Drapkin, Establishment of patient-derived tumor xenograft models of epithelial ovarian cancer for preclinical evaluation of novel therapeutics. Clin. Cancer Res. 23, 1263–1273 (2017)
31.
M.D. Topp, L. Hartley, M. Cook, V. Heong, E. Boehm, L. McShane, J. Pyman, O. McNally, S. Ananda, M. Harrell, D. Etemadmoghadam, L. Galletta, K. Alsop, G. Mitchell, S.B. Fox, J.B. Kerr, K.J. Hutt, S.H. Kaufmann, E.M. Swisher, D.D. Bowtell, M.J. Wakefield, C.L. Scott, A.O.C. Study, Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Mol. Oncol. 8, 656–668 (2014)CrossRef
32.
S.J. Weroha, M.A. Becker, S. Enderica-Gonzalez, S.C. Harrington, A.L. Oberg, M.J. Maurer, S.E. Perkins, M. AlHilli, K.A. Butler, S. McKinstry, S. Fink, R.B. Jenkins, X. Hou, K.R. Kalli, K.M. Goodman, J.N. Sarkaria, B.Y. Karlan, A. Kumar, S.H. Kaufmann, L.C. Hartmann, P. Haluska, Tumorgrafts as in vivo surrogates for women with ovarian cancer. Clin. Cancer Res. 20, 1288–1297 (2014)CrossRef
33.
Y.Y. Yangjiong Xiao, D. Gao, W. Jin, P. Jiang, Y. Li et al., Inhibition of CDC25B with WG-391D impedes the tumorigenesis of ovarian cancer. Front. Oncol. 9, 236 (2019)
34.
S.D. Knight, N.D. Adams, J.L. Burgess, A.M. Chaudhari, M.G. Darcy, C.A. Donatelli, J.I. Luengo, K.A. Newlander, C.A. Parrish, L.H. Ridgers, M.A. Sarpong, S.J. Schmidt, G.S. Van Aller, J.D. Carson, M.A. Diamond, P.A. Elkins, C.M. Gardiner, E. Garver, S.A. Gilbert, R.R. Gontarek, J.R. Jackson, K.L. Kershner, L. Luo, K. Raha, C.S. Sherk, C.M. Sung, D. Sutton, P.J. Tummino, R.J. Wegrzyn, K.R. Auger, D. Dhanak, Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med. Chem. Lett. 1, 39–43 (2010)
35.
P. Munster, R. Aggarwal, D. Hong, J.H. Schellens, R. van der Noll, J. Specht, P.O. Witteveen, T.L. Werner, E.C. Dees, E. Bergsland, N. Agarwal, J.F. Kleha, M. Durante, L. Adams, D.A. Smith, T.A. Lampkin, S.R. Morris, R. Kurzrock, First-inhuman phase I study of GSK2126458, an oral pan-class I phosphatidylinositol-3-kinase inhibitor, in patients with advanced solid tumor malignancies. Clin. Cancer Res. 22, 1932–1939 (2016)
36.
M. Kanehisa, M. Araki, S. Goto, M. Hattori, M. Hirakawa, M. Itoh, T. Katayama, S. Kawashima, S. Okuda, T. Tokimatsu, Y. Yamanishi, KEGG for linking genomes to life and the environment. Nucleic Acids Res. 36, D480–D484 (2008)CrossRef
37.
S. Domcke, R. Sinha, D.A. Levine, C. Sander, N. Schultz, Evaluating cell lines as tumour models by comparison of genomic profiles. Nat. Commun. 4, 2126 (2013)CrossRef
38.
C.M. Beaufort, J.C. Helmijr, A.M. Piskorz, M. Hoogstraat, K. Ruigrok-Ritstier, N. Besselink, M. Murtaza, I.W.F. van, A.A. Heine, M. Smid, M.J. Koudijs, J.D. Brenton, E.M. Berns, J. Helleman, Ovarian cancer cell line panel (OCCP): clinical importance of in vitro morphological subtypes. PLoS One 9, e103988 (2014)
39.
H. Yoshida, W. Cheng, J. Hung, D. Montell, E. Geisbrecht, D. Rosen, J. Liu, H. Naora, Lessons from border cell migration in the Drosophila ovary: A role for myosin VI in dissemination of human ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 101, 8144–8149 (2004)CrossRef
40.
S. Sale, S. Orsulic, Models of ovarian cancer metastasis: Murine models. Drug Discov. Today Dis. Models 3, 149–154 (2006)
41.
M.A. Eckert, F. Coscia, A. Chryplewicz, J.W. Chang, K.M. Hernandez, S. Pan, S.M. Tienda, D.A. Nahotko, G. Li, I. Blazenovic, R.R. Lastra, M. Curtis, S.D. Yamada, R. Perets, S.M. McGregor, J. Andrade, O. Fiehn, R.E. Moellering, M. Mann, E. Lengyel, Proteomics reveals NNMT as a master metabolic regulator of cancer-associated fibroblasts. Nature 569, 723–728 (2019)CrossRef
42.
L. Chen, S.M. Park, A.V. Tumanov, A. Hau, K. Sawada, C. Feig, J.R. Turner, Y.X. Fu, I.L. Romero, E. Lengyel, M.E. Peter, CD95 promotes tumour growth. Nature 465, 492–496 (2010)CrossRef
43.
L. Chen, X. Cheng, W. Tu, Z. Qi, H. Li, F. Liu, Y. Yang, Z. Zhang, Z. Wang, Apatinib inhibits glycolysis by suppressing the VEGFR2/AKT1/SOX5/GLUT4 signaling pathway in ovarian cancer cells. Cell. Oncol. 42, 679–690 (2019)
44.
Z.C. Dobbin, C.N. Landen, The importance of the PI3K/AKT/MTOR pathway in the progression of ovarian cancer. Int. J. Mol. Sci. 14, 8213–8227 (2013)CrossRef
45.
46.
A. Gul, B. Leyland-Jones, N. Dey, P. De, A combination of the PI3K pathway inhibitor plus cell cycle pathway inhibitor to combat endocrine resistance in hormone receptor-positive breast cancer: a genomic algorithm-based treatment approach. Am. J. Cancer Res. 8, 2359–2376 (2018)PubMedPubMedCentral
47.
48.
E. Leung, J.E. Kim, G.W. Rewcastle, G.J. Finlay, B.C. Baguley, Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells. Cancer Biol. Ther. 11, 938–946 (2011)CrossRef
49.
50.
J.E. Grilley-Olson, P.L. Bedard, A. Fasolo, M. Cornfeld, L. Cartee, A.R. Razak, L.A. Stayner, Y. Wu, R. Greenwood, R. Singh, C.B. Lee, J. Bendell, H.A. Burris, G. Del Conte, C. Sessa, J.R. Infante, A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors. Invest. New Drugs 34, 740–749 (2016)CrossRef
51.
S. Vaidhyanathan, B. Wilken-Resman, D.J. Ma, K.E. Parrish, R.K. Mittapalli, B.L. Carlson, J.N. Sarkaria, W.F. Elmquist, Factors influencing the central nervous system distribution of a novel phosphoinositide 3-kinase/mammalian target of rapamycin inhibitor GSK2126458: Implications for overcoming resistance with combination therapy for melanoma brain metastases. J. Pharmacol. Exp. Ther. 356, 251–259 (2016)
52.
V.A. Kuznetsov, Z. Tang, A.V. Ivshina, Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets. BMC Genom. 18, 692 (2017)CrossRef
53.
P. Kanlikilicer, M.H. Rashed, R. Bayraktar, R. Mitra, C. Ivan, B. Aslan, X. Zhang, J. Filant, A.M. Silva, C. Rodriguez-Aguayo, E. Bayraktar, M. Pichler, B. Ozpolat, G.A. Calin, A.K. Sood, G. Lopez-Berestein, Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res. 76, 7194–7207 (2016)
54.
M.L. Gasparri, Z.M. Besharat, A.A. Farooqi, S. Khalid, K. Taghavi, R.A. Besharat, C. Sabato, A. Papadia, P.B. Panici, M.D. Mueller, E. Ferretti, MiRNAs and their interplay with PI3K/AKT/mTOR pathway in ovarian cancer cells: a potential role in platinum resistance. J. Cancer Res. Clin. Oncol. 144, 2313–2318 (2018)CrossRef
Metadata
Title
The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis
Authors
Yangjiong Xiao
Yang Yu
Pengcheng Jiang
Yuhong Li
Chao Wang
Rong Zhang
Publication date
01-08-2020
Publisher
Springer Netherlands
Published in
Cellular Oncology / Issue 4/2020
Print ISSN: 2211-3428
Electronic ISSN: 2211-3436
DOI
https://doi.org/10.1007/s13402-020-00514-8

Other articles of this Issue 4/2020

Cellular Oncology 4/2020 Go to the issue

Original paper

A lectin-based glycomic approach identifies FUT8 as a driver of radioresistance in oesophageal squamous cell carcinoma

Review

Modeling of the immune response in the pathogenesis of solid tumors and its prognostic significance

Review

Current insights into the metastasis of epithelial ovarian cancer - hopes and hurdles

Original paper

Overexpression of Sal-like protein 4 in head and neck cancer: epigenetic effects and clinical correlations

Review

Functional and metabolic targeting of natural killer cells to solid tumors

Original paper

The hedgehog pathway regulates cancer stem cells in serous adenocarcinoma of the ovary
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits